Loading...
TAK logo

Takeda Pharmaceutical Company LimitedNYSE:TAK Stock Report

Market Cap US$48.6b
Share Price
US$15.60
US$19.43
19.7% undervalued intrinsic discount
1Y4.3%
7D-2.3%
1D
Portfolio Value
​
View

Takeda Pharmaceutical Company Limited

NYSE:TAK Stock Report

Market Cap: US$48.6b

Takeda Pharmaceutical (TAK) Stock Overview

Engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More details

TAK fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance3/6
Financial Health4/6
Dividends4/6

Rewards

Trading at 69.7% below our estimate of its fair value

Earnings are forecast to grow 17.57% per year

Earnings grew by 77.7% over the past year

Risk Analysis

Large one-off items impacting financial results

Has a high level of debt

Dividend of 4.14% is not well covered by earnings


TAK Community Fair Values

Create Narrative

See what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Takeda Pharmaceutical Company Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Takeda Pharmaceutical
Historical stock prices
Current Share PriceJP¥15.60
52 Week HighJP¥18.90
52 Week LowJP¥12.99
Beta0.089
1 Month Change-5.22%
3 Month Change-13.67%
1 Year Change4.28%
3 Year Change-3.76%
5 Year Change-9.35%
Change since IPO-26.59%

Recent News & Updates

Seeking Alpha • May 18

Takeda's Rich Pipeline Optionality Is Worth A 'Buy'

Summary TAK’s FY2025 revenue was about $28.4 billion, which was down 1.7% YoY due to Vyvanse’s generic pressure. This remains a growth headwind until their first wave launches. Management is pairing a new transformation program with cost-cutting measures that will target over $1.3 billion in annualized gross savings by FY2028. As such, I believe TAK’s long-term bull case depends on three near-term launch candidates (i.e., the first wave) with oveporexton, rusfertide, and zasocitinib. TAK’s valuation is reasonable enough to justify a “Buy” during this inflection year. I feel the market may be underappreciating the potential of that first wave of assets. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • May 18

Takeda's Rich Pipeline Optionality Is Worth A 'Buy'

Summary TAK’s FY2025 revenue was about $28.4 billion, which was down 1.7% YoY due to Vyvanse’s generic pressure. This remains a growth headwind until their first wave launches. Management is pairing a new transformation program with cost-cutting measures that will target over $1.3 billion in annualized gross savings by FY2028. As such, I believe TAK’s long-term bull case depends on three near-term launch candidates (i.e., the first wave) with oveporexton, rusfertide, and zasocitinib. TAK’s valuation is reasonable enough to justify a “Buy” during this inflection year. I feel the market may be underappreciating the potential of that first wave of assets. Read the full article on Seeking Alpha
Seeking Alpha • Mar 13

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds

Summary Japan-based Takeda Pharmaceutical, which has its ADR listed on the NYSE, gets a buy rating today, agreeing with the analyst consensus. Besides a diverse drug portfolio across multiple segments, they have a robust drug discovery pipeline to meet future clinical demand. The firm has been a proven cash flow generator, with an above-average dividend yield above +4%, and modest leverage risk. Some challenges are the stock appears overvalued on forward earnings multiple, and could use improvement to its profit margin compared to big pharma peers. Read the full article on Seeking Alpha
Seeking Alpha • Jan 31

Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued

Summary Takeda Pharmaceutical offers attractive dividends and has a low price/book ratio, making it appealing despite recent price drops and US policy uncertainties. The company reported strong Q3 earnings, raised full-year FY2025 guidance, and announced a new CEO and a significant share repurchase program. Revenue and operating income exceeded expectations due to a shortage of generic Vyvanse, favorable exchange rates, and reduced amortization of intangible assets. US policy and tariffs pose risks, but Takeda's strong dividend yield and strategic moves make it a worthwhile investment at current prices. Read the full article on Seeking Alpha
Seeking Alpha • Dec 07

Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors

Summary Takeda Pharmaceutical offers a high dividend yield, but its sustainability is questionable due to exchange rate risks and a payout ratio often exceeding 100%. Despite growth in segments like Livtencity and Qdenga, high debt and weak currency make Takeda a risky dividend investment. The devaluation of the yen against the dollar significantly impacts revenue growth and dividend stability for U.S. investors. Key drugs like Entyvio face patent expiration, while Vyvanse has already lost U.S. exclusivity, posing risks to future revenue streams. Read the full article on Seeking Alpha
Seeking Alpha • Oct 07

Takeda Pharmaceuticals: An Interesting Option For Income Investors

Summary Takeda Pharmaceuticals (NYSE: TAK) offers a strong cash position and above-average dividend yield, making it an attractive option for income investors seeking international pharma exposure. The company's price/book value of 0.92 suggests it may be undervalued, presenting a potential long-term investment opportunity at a modest price. Risks include foreign currency exchange rate fluctuations and global pressure to reduce drug prices, which could impact profitability and margins. Despite intense competition, Takeda's steady revenue growth and strong dividend yield of 4.24% make it a solid addition to a diversified income portfolio. Read the full article on Seeking Alpha
Seeking Alpha • Jun 06

Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk

Summary Takeda Pharmaceutical Company's shares have not been able to overcome overhead resistance and are likely to test their October 2022 lows. TAK stock has declined by over 17% since our previous commentary, while the S&P 500 has rallied over 36%. Takeda's profitability trends show a decrease in core EBIT, but management remains optimistic about the company's pipeline & growth and launch products. Read the full article on Seeking Alpha
Seeking Alpha • Mar 03

Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits

Summary Takeda Pharmaceutical reports 4.6% YoY revenue growth in Q3 2023, driven by positive forex moves and pipeline advancements. Takeda receives FDA approval for novel drugs EOHILIA, FRUZAQLA, and ADZYNMA, expanding its commercialized product portfolio. Takeda focuses on R&D and digital transformation, including the use of AI solutions, to enhance innovation and treatment options for patients. Read the full article on Seeking Alpha

Shareholder Returns

TAKUS PharmaceuticalsUS Market
7D-2.3%1.6%-2.8%
1Y4.3%40.4%22.8%

Return vs Industry: TAK underperformed the US Pharmaceuticals industry which returned 40.4% over the past year.

Return vs Market: TAK underperformed the US Market which returned 23.5% over the past year.

Price Volatility

Is TAK's price volatile compared to industry and market?
TAK volatility
TAK Average Weekly Movement3.2%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: TAK has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: TAK's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
178147,455Christophe P. Weberwww.takeda.com

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.

Takeda Pharmaceutical Company Limited Fundamentals Summary

How do Takeda Pharmaceutical's earnings and revenue compare to its market cap?
TAK fundamental statistics
Market capUS$48.58b
Earnings (TTM)US$1.20b
Revenue (TTM)US$28.13b
40.6x
P/E Ratio
1.7x
P/S Ratio

Is TAK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TAK income statement (TTM)
RevenueJP¥4.51t
Cost of RevenueJP¥1.57t
Gross ProfitJP¥2.93t
Other ExpensesJP¥2.74t
EarningsJP¥191.76b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Jul 30, 2026

Earnings per share (EPS)121.38
Gross Margin65.12%
Net Profit Margin4.26%
Debt/Equity Ratio62.8%

How did TAK perform over the long term?

See historical performance and comparison

Dividends

4.1%
Current Dividend Yield
164%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/07 02:35
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Takeda Pharmaceutical Company Limited is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Miki SogiBernstein
Koichi MameganoBofA Global Research